Pritesh Jain

Pritesh Jain has a strong background in animal physiology and pharmacology, with a focus on studying mechanisms of alveolar hypoxia-induced pulmonary vasoconstriction and screening drugs for the treatment of pulmonary hypertension. Pritesh has held various research positions, including Scientist In Vivo at Keros Therapeutics starting in 2023, Researcher at the University of Minnesota from November 2022 to April 2023, and Postdoctoral Fellow at the Ottawa Hospital Research Institute from August 2021 to November 2022. Prior to these roles, Pritesh worked as a Postdoctoral Research Associate at the University of California San Diego from January 2019 to July 2022, a Postdoctoral Research Associate at the University of Arizona College of Medicine – Tucson from October 2017 to December 2018, and a Postdoctoral Scientist at the Second Faculty of Medicine, Charles University in Prague from April 2015 to September 2017. Pritesh also served as a PHD Researcher at the Ludwig Boltzmann Institute for Lung Vascular Research in Graz, Austria from October 2010 onwards. Pritesh has contributed to multiple projects, guided PhD students, and taught physiology to medical students.

Pritesh Jain has a diverse education history. Pritesh started by obtaining a Bachelor of Pharmacy (BPharm) degree from Savitribai Phule Pune University in 2008. Following that, they pursued a Master of Science (MSc) degree in Pharmacology from Nottingham Trent University, which they completed in 2009. Subsequently, Pritesh enrolled in the Medical University of Graz in Austria, where they earned a Doctor of Philosophy (PhD) degree in Molecular Medicine in 2014.

In addition to their academic achievements, Pritesh holds a certification called MicroMBA from the University of California, San Diego - Rady School of Management. However, the specific details regarding the month and year of obtaining this certification are not provided.